C
ACAD icon

Covestor’s Acadia Pharmaceuticals ACAD Stock Holding History

Covestor’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118K Buy
4,682
+1,559
+50% +$34.3K 0.07% 277
2026
Q1 		$70K Sell
3,123
-7,572
-71% -$181K 0.05% 480
2025
Q4 		$286K Buy
10,695
+281
+3% +$6.71K 0.15% 115
2025
Q3 		$222K Sell
10,414
-5,571
-35% -$132K 0.12% 169
2025
Q2 		$345K Buy
15,985
+15,135
+1,781% +$281K 0.2% 58
2025
Q1 		$15K Buy
850
+6
+0.7% +$109 0.01% 1275
2024
Q4 		$16K Buy
844
+175
+26% +$2.83K 0.01% 1286
2024
Q3 		$10K Sell
669
-2
-0.3% -$33 0.01% 1536
2024
Q2 		$11K Sell
671
-1,361
-67% -$22K 0.01% 1445
2024
Q1 		$38K Buy
2,032
+840
+70% +$20.8K 0.02% 978
2023
Q4 		$37K Buy
1,192
+608
+104% +$14.5K 0.03% 967
2023
Q3 		$12K Buy
584
+572
+4,767% +$15.5K 0.01% 1315
2023
Q2 		$0 Hold
12
– – ﹤0.01% 2057
2023
Q1 		$0 Sell
12
-3
-20% -$57 ﹤0.01% 1931
2022
Q4 		$0 Sell
15
-14
-48% -$219 ﹤0.01% 1979
2022
Q3 		$0 Buy
29
+10
+53% +$162 ﹤0.01% 1908
2022
Q2 		$0 Sell
19
-143
-88% -$2.67K ﹤0.01% 1840
2022
Q1 		$4K Sell
162
-6
-4% -$145 ﹤0.01% 1520
2021
Q4 		$4K Buy
+168
New +$3.38K 0.01% 1365

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Covestor's ACAD Position: Q2 2026 in Review

Covestor increased its Acadia Pharmaceuticals (ACAD) stake by 50% in Q2 2026, buying an estimated $34.3K and bringing the position to 4,682 shares worth $118K. The position accounts for 0.07% of the portfolio, ranked #277.

Covestor first reported a position in ACAD in Q4 2021 and has held it in 19 quarters since. The position peaked at $345K in Q2 2025. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Covestor held 4,682 shares of Acadia Pharmaceuticals worth $118K as of Q2 2026.
  • Covestor bought 1,559 Acadia Pharmaceuticals shares in Q2 2026, an estimated $34.3K.
  • Acadia Pharmaceuticals made up 0.07% of Covestor's portfolio in Q2 2026, its #277 holding.
  • Covestor first reported a position in Acadia Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • Covestor's Acadia Pharmaceuticals position peaked at $345K in Q2 2025.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.